These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31751381)

  • 1. Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-A.
    Torres D; Hou X; Bale L; Heinzen EP; Maurer MJ; Zanfagnin V; Oberg AL; Conover C; Weroha SJ
    PLoS One; 2019; 14(11):e0224564. PubMed ID: 31751381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel neutralizing antibody targeting pregnancy-associated plasma protein-a inhibits ovarian cancer growth and ascites accumulation in patient mouse tumorgrafts.
    Becker MA; Haluska P; Bale LK; Oxvig C; Conover CA
    Mol Cancer Ther; 2015 Apr; 14(4):973-81. PubMed ID: 25695953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft.
    Glaser G; Weroha SJ; Becker MA; Hou X; Enderica-Gonzalez S; Harrington SC; Haluska P
    PLoS One; 2015; 10(5):e0126867. PubMed ID: 25962155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flavonoids Restore Platinum Drug Sensitivity to Ovarian Carcinoma Cells in a Phospho-ERK1/2-Dependent Fashion.
    Koren Carmi Y; Mahmoud H; Khamaisi H; Adawi R; Gopas J; Mahajna J
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32906729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts.
    Ricci F; Guffanti F; Damia G; Broggini M
    Mol Cancer; 2017 May; 16(1):97. PubMed ID: 28558767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between in vitro platinum resistance in the EDR assay and clinical outcomes for ovarian cancer patients.
    Holloway RW; Mehta RS; Finkler NJ; Li KT; McLaren CE; Parker RJ; Fruehauf JP
    Gynecol Oncol; 2002 Oct; 87(1):8-16. PubMed ID: 12468336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translational immune correlates of indirect antibody immunization in a randomized phase II study using scheduled combination therapy with carboplatin/paclitaxel plus oregovomab in ovarian cancer patients.
    Battaglia A; Buzzonetti A; Fossati M; Scambia G; Fattorossi A; Madiyalakan MR; Mahnke YD; Nicodemus C
    Cancer Immunol Immunother; 2020 Mar; 69(3):383-397. PubMed ID: 31897661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting HER2 in patient-derived xenograft ovarian cancer models sensitizes tumors to chemotherapy.
    Harris FR; Zhang P; Yang L; Hou X; Leventakos K; Weroha SJ; Vasmatzis G; Kovtun IV
    Mol Oncol; 2019 Feb; 13(2):132-152. PubMed ID: 30499260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indirect targeting of IGF receptor signaling in vivo by substrate-selective inhibition of PAPP-A proteolytic activity.
    Mikkelsen JH; Resch ZT; Kalra B; Savjani G; Kumar A; Conover CA; Oxvig C
    Oncotarget; 2014 Feb; 5(4):1014-25. PubMed ID: 24572990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Knockdown of platinum-induced growth differentiation factor 15 abrogates p27-mediated tumor growth delay in the chemoresistant ovarian cancer model A2780cis.
    Meier JC; Haendler B; Seidel H; Groth P; Adams R; Ziegelbauer K; Kreft B; Beckmann G; Sommer A; Kopitz C
    Cancer Med; 2015 Feb; 4(2):253-67. PubMed ID: 25490861
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DGKA Provides Platinum Resistance in Ovarian Cancer Through Activation of c-JUN-WEE1 Signaling.
    Li J; Pan C; Boese AC; Kang J; Umano AD; Magliocca KR; Yang W; Zhang Y; Lonial S; Jin L; Kang S
    Clin Cancer Res; 2020 Jul; 26(14):3843-3855. PubMed ID: 32341033
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A chemoresponse assay for prediction of platinum resistance in primary ovarian cancer.
    Krivak TC; Lele S; Richard S; Secord AA; Leath CA; Brower SL; Tian C; Moore RG
    Am J Obstet Gynecol; 2014 Jul; 211(1):68.e1-8. PubMed ID: 24530815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of α4β1 integrin increases ovarian cancer response to carboplatin.
    Scalici JM; Harrer C; Allen A; Jazaeri A; Atkins KA; McLachlan KR; Slack-Davis JK
    Gynecol Oncol; 2014 Feb; 132(2):455-61. PubMed ID: 24378876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secretory leukocyte protease inhibitor antagonizes paclitaxel in ovarian cancer cells.
    Rasool N; LaRochelle W; Zhong H; Ara G; Cohen J; Kohn EC
    Clin Cancer Res; 2010 Jan; 16(2):600-9. PubMed ID: 20068074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum- and glucocorticoid- inducible kinase 2, SGK2, is a novel autophagy regulator and modulates platinum drugs response in cancer cells.
    Ranzuglia V; Lorenzon I; Pellarin I; Sonego M; Dall'Acqua A; D'Andrea S; Lovisa S; Segatto I; Coan M; Polesel J; Serraino D; Sabatelli P; Spessotto P; Belletti B; Baldassarre G; Schiappacassi M
    Oncogene; 2020 Oct; 39(40):6370-6386. PubMed ID: 32848212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
    Oza AM; Cibula D; Benzaquen AO; Poole C; Mathijssen RH; Sonke GS; Colombo N; Špaček J; Vuylsteke P; Hirte H; Mahner S; Plante M; Schmalfeldt B; Mackay H; Rowbottom J; Lowe ES; Dougherty B; Barrett JC; Friedlander M
    Lancet Oncol; 2015 Jan; 16(1):87-97. PubMed ID: 25481791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of paclitaxel and carboplatin therapies by CCL2 blockade in ovarian cancers.
    Moisan F; Francisco EB; Brozovic A; Duran GE; Wang YC; Chaturvedi S; Seetharam S; Snyder LA; Doshi P; Sikic BI
    Mol Oncol; 2014 Oct; 8(7):1231-9. PubMed ID: 24816187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cediranib combined with chemotherapy reduces tumor dissemination and prolongs the survival of mice bearing patient-derived ovarian cancer xenografts with different responsiveness to cisplatin.
    Decio A; Cesca M; Bizzaro F; Porcu L; Bettolini R; Ubezio P; Taraboletti G; Belotti D; Giavazzi R
    Clin Exp Metastasis; 2015 Oct; 32(7):647-58. PubMed ID: 26185056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer.
    Chen Y; Camacho SC; Silvers TR; Razak AR; Gabrail NY; Gerecitano JF; Kalir E; Pereira E; Evans BR; Ramus SJ; Huang F; Priedigkeit N; Rodriguez E; Donovan M; Khan F; Kalir T; Sebra R; Uzilov A; Chen R; Sinha R; Halpert R; Billaud JN; Shacham S; McCauley D; Landesman Y; Rashal T; Kauffman M; Mirza MR; Mau-Sørensen M; Dottino P; Martignetti JA
    Clin Cancer Res; 2017 Mar; 23(6):1552-1563. PubMed ID: 27649553
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.